683 related articles for article (PubMed ID: 15930341)
21. [Association of TP53 gene polymorphisms with genetic susceptibility to liver metastases of colorectal cancer].
Wang AZ; Zhu ZZ; Cong WM
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Apr; 25(2):168-71. PubMed ID: 18393238
[TBL] [Abstract][Full Text] [Related]
22. Deregulated expression of c-mos in non-small cell lung carcinomas: relationship with p53 status, genomic instability, and tumor kinetics.
Gorgoulis VG; Zacharatos P; Mariatos G; Liloglou T; Kokotas S; Kastrinakis N; Kotsinas A; Athanasiou A; Foukas P; Zoumpourlis V; Kletsas D; Ikonomopoulos J; Asimacopoulos PJ; Kittas C; Field JK
Cancer Res; 2001 Jan; 61(2):538-49. PubMed ID: 11212247
[TBL] [Abstract][Full Text] [Related]
23. TP53 mutations do not correlate with locoregional recurrence in stage I tongue carcinomas.
Högmo A; Börresen-Dale AL; Blegen H; Lindholm J; Kuylenstierna R; Auer G; Munck-Wikland E
Anticancer Res; 1999; 19(4C):3433-8. PubMed ID: 10629631
[TBL] [Abstract][Full Text] [Related]
24. Harmonized microarray/mutation scanning analysis of TP53 mutations in undissected colorectal tumors.
Favis R; Huang J; Gerry NP; Culliford A; Paty P; Soussi T; Barany F
Hum Mutat; 2004 Jul; 24(1):63-75. PubMed ID: 15221790
[TBL] [Abstract][Full Text] [Related]
25. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
26. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
27. Association of angiogenesis markers with lymph node metastasis in early colorectal cancer.
Iddings DM; Koda EA; Grewal SS; Parker R; Saha S; Bilchik A
Arch Surg; 2007 Aug; 142(8):738-44; discussion 744-5. PubMed ID: 17709727
[TBL] [Abstract][Full Text] [Related]
28. [Significance of p53 and VEGF expression in liver metastasis from colorectal cancer].
Yamamura T; Matsuzaki H; Ozasa T; Matsuoka H; Tanaka K; Oikawa H; Akaishi O; Tsukikawa S; Yamaguchi S
Gan To Kagaku Ryoho; 1998 Jul; 25(9):1355-7. PubMed ID: 9703827
[TBL] [Abstract][Full Text] [Related]
29. Expression of vascular endothelial growth factor and receptor flk-1 in colon cancer liver metastases.
Cheng J; Slavin RE; Gallagher JA; Zhu G; Biehl TR; Swanstrom LL; Hansen PD
J Hepatobiliary Pancreat Surg; 2004; 11(3):164-70. PubMed ID: 15235888
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.
Ikeda S; Shimizu Y; Fujimori M; Ishizaki Y; Kurihara T; Ojima Y; Okajima M; Asahara T
Clin Cancer Res; 2003 Nov; 9(15):5660-5. PubMed ID: 14654549
[TBL] [Abstract][Full Text] [Related]
31. TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.
Børresen-Dale AL; Lothe RA; Meling GI; Hainaut P; Rognum TO; Skovlund E
Clin Cancer Res; 1998 Jan; 4(1):203-10. PubMed ID: 9516972
[TBL] [Abstract][Full Text] [Related]
32. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
[TBL] [Abstract][Full Text] [Related]
33. Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.
Albanese I; Scibetta AG; Migliavacca M; Russo A; Bazan V; Tomasino RM; Colomba P; Tagliavia M; La Farina M
Biochem Biophys Res Commun; 2004 Dec; 325(3):784-91. PubMed ID: 15541358
[TBL] [Abstract][Full Text] [Related]
34. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
36. Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases.
Kern A; Taubert H; Scheele J; Rudroff C; Mothes H; Kappler M; Bartel F; Richter KK
Int J Oncol; 2002 Aug; 21(2):243-9. PubMed ID: 12118317
[TBL] [Abstract][Full Text] [Related]
37. Increased incidence of p53 mutations is associated with hepatic metastasis in colorectal neoplastic progression.
Kastrinakis WV; Ramchurren N; Rieger KM; Hess DT; Loda M; Steele G; Summerhayes IC
Oncogene; 1995 Aug; 11(4):647-52. PubMed ID: 7651727
[TBL] [Abstract][Full Text] [Related]
38. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.
Etienne-Grimaldi MC; Formento JL; Francoual M; François E; Formento P; Renée N; Laurent-Puig P; Chazal M; Benchimol D; Delpero JR; Letoublon C; Pezet D; Seitz JF; Milano G
Clin Cancer Res; 2008 Aug; 14(15):4830-5. PubMed ID: 18676755
[TBL] [Abstract][Full Text] [Related]
39. Cutaneous hidradenocarcinoma: a clinicopathological, immunohistochemical, and molecular biologic study of 14 cases, including Her2/neu gene expression/amplification, TP53 gene mutation analysis, and t(11;19) translocation.
Kazakov DV; Ivan D; Kutzner H; Spagnolo DV; Grossmann P; Vanecek T; Sima R; Kacerovska D; Shelekhova KV; Denisjuk N; Hillen U; Kuroda N; Mukensnabl P; Danis D; Michal M
Am J Dermatopathol; 2009 May; 31(3):236-47. PubMed ID: 19384064
[TBL] [Abstract][Full Text] [Related]
40. P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients.
Khan ZA; Jonas SK; Le-Marer N; Patel H; Wharton RQ; Tarragona A; Ivison A; Allen-Mersh TG
Clin Cancer Res; 2000 Sep; 6(9):3499-504. PubMed ID: 10999735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
